Differences

This shows you the differences between two versions of the page.

--- jc [2024/05/14 17:29] – admin
+++ jc [2025/10/30 16:16] (current) – admin
@@ Line 1: / Line 1: @@
 ===== Ideas =====
-  * [[https://doi.org/10.1056/NEJMoa2312572 | DANGER-SHOCK]]
+  * Airway
-    * **Finding**: Impella CP reduces mortality
+    * [[https://doi.org/10.1001/jama.2024.0762 | Hyperangulated VL vs Standard DL in Surgical Patients]]
-    * **Significance**: First trial to show mortality benefit from MCS
+      * **Finding**: First-pass intubation failure: hyperangulated VL 1.7% vs DL 7.6%
-  * [[https:doi.org/10.1001/jama.2024.0762 | Hyperangulated VL vs Standard DL in Surgical Patients]]
+      * **Significance**: More evidence VL is better as first-line?
-    * **Finding**: First-pass intubation failure: hyperangulated VL 1.7% vs DL 7.6%
+    * [[https://doi.org/10.1111/anae.15985 | Mac Geometry VL vs Mac DL]]
-    * **Significance**: More evidence VL is better as first-line?
+      * **Finding:** VL had better first-pass success than DL
+  * CARDS
+    * [[https://doi.org/10.1016/j.resuscitation.2024.110360 | IV vs IO for OHCA]]
+      * Finding: IV assoc with better survival and neuro fav outcomes
+    * [[https://doi.org/10.1056/NEJMoa2307983 | MINT: Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia]]
+      * **Finding**: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days.
+  * CCM
+    * [[http://doi.org/10.1056/NEJMoa2502136 | No Art Line in Shock]]
+    * [[https://doi.org/10.1056/NEJMoa2404245 | Pantoprazole for MV GI bleed ppx]]
+      * **Finding**: reduces GIB, no mortality benefit
+      * [[https://doi.org/10.1097/CCM.0000000000006376 | Calcium for hyperK]]
+      * **Finding**: not via membrane stabilization
+  * MCS
+    * [[https://doi.org/10.1056/NEJMoa2312572 | DANGER-SHOCK]]
+      * **Finding**: Impella CP reduces mortality
+      * **Significance**: First trial to show mortality benefit from MCS
+  * PULM
+    * [[https://doi.org/10.1056/NEJMoa2507100 | Steroids in Non-Severe CAP]]
+    * [[https://doi.org/10.1056/NEJMoa2411664 | brensocatib for bronchiectasis]]
+    * [[ https://www.nejm.org/doi/full/10.1056/NEJMoa2406673 | Depemokimab]]
+    * [[https://www.nejm.org/doi/full/10.1056/NEJMoa2409712 | Inebilizumab for Treatment of IgG4-Related Disease]]
+  * GI
+    * [[https://doi.org/10.1097/HEP.0000000000000817 | Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis]]
+      * **Finding**: in Child-Pugh B or C with UGIB, TXA improves bleeding control vs placebo
+  * Trauma
+    * [[https://doi.org/10.1001/jama.2023.20850 | UK-REBOA]]
+      * **Finding**: In trauma patients with exsanguinating hemorrhage, a strategy of REBOA and standard care in the emergency department does not reduce, and may increase, mortality compared with standard care alone.

ewrobbins.com

User Tools

Site Tools

Differences

Page Tools